Objective: To evaluate the safety and efficacy of a low dose of flutamide (125 mg/day) in maintaining the clinical results already obtained using a higher dose (250 mg/day), in women suffering from hirsutism. Method: Forty-three women suffering from hirsutism of varying origin received 250 mg/day of flutamide as an initial treatment for 12 months and, subsequently, 125 mg/day of flutamide for an additional 12 months as a maintenance treatment. Hirsutism was evaluated by the Ferriman-Gallwey score, and hair diameter and hair growth rate were determined by a special image analysis processor. Biochemical, clinical and hormonal parameters were evaluated in basal conditions and every 2–6 months. Results: The significant decrease in the hirsutism score, hair diameter and hair growth rate during the initial treatment period was confirmed at the end of the maintenance treatment period. Androgen levels decreased up to the end of the initial treatment period and partially decreased during the maintenance treatment. During the initial treatment period, 4 subjects showed an increase of aspartate aminotransferase and alanine aminotransferase and dropped out. During the maintenance treatment period, no side effects or complications were observed. Conclusion: Satisfactory management of hirsutism with flutamide seems to be represented by an initial treatment period using 250 mg/day to achieve satisfactory results, followed by a long maintenance treatment period using 125 mg/day.

1.
Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli B, Bagnoli A, Paradisi R, Flamigni C: A prospective randomized trial comparing low-dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304–1310.
2.
Yucelten D, Erenus M, Gurbuz O, Durmusoglu F: Recurrence rate of hirsutism after three different antiandrogen therapies. J Am Acad Dermatol 1999;41:64–68.
3.
Rittmaster RS: Antiandrogen treatment of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:409–421.
4.
Motta T, Maggi G, Perra M, Azzolari E, Casazza S, D’Alberton A: Flutamide in the treatment of hirsutism. Int J Gynecol Obstet 1991;36:155–157.
5.
Marcondes J, Minnani SL, Luthold WW, Wajchemberg BL, Samojlik E, Kirschner P: Treatment of hirsutism in women with flutamide. Fertil Steril 1992;57:543–547.
6.
Fruzzetti F, De Lorenzo D, Ricci C, Fioretti P: Clinical and endocrine effects of flutamide in hyperandrogenic women. Fertil Steril 1993;60:806–813.
7.
Couzinet B, Pholsena M, Young J, Schaison G: The impact of a pure antiandrogen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin Endocrinol 1993;39:157–162.
8.
Ciotta L, Cianci A, Marletta E, Pisana L, Agliano A, Palumbo G: Treatment of hirsutism with flutamide and a low-dose oral contraceptive in polycystic ovarian disease patients. Fertil Steril 1994;62:1129–1135.
9.
Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F: Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil Steril 1994;61:281–287.
10.
Dodin S, Faure N, Cedrin I, Mechain C, Turcot-Lemay L, Guy J, Lemay A: Clinical efficacy and safety of low-doses of flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin Endocrinol 1995;43:575–582.
11.
Moghetti P, Castello R, Negri C, Tosi F, Magnani CM, Fontanarosa MC, Armannini D, Muggeo M: Flutamide in the treatment of hirsutism: Long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil Steril 1995;64:511–517.
12.
Muderris II, Bayram F, Sahin Y, Kelestimur F, Tutus A, Ayata D: The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertil Steril 1996;66:220–222.
13.
Muderris II, Bayram F, Sahin Y, Kelestimur F: A comparison between two doses of flutamide (250 and 500 mg/day) in the treatment of hirsutism. Fertil Steril 1997;68:644–647.
14.
Wilow I, Fourcroy JL: Flutamide hepatotoxicity. J Urol 1996;155:209–212.
15.
Azziz R, Zacur HA: 21-Hydroxylase deficiency in female hyperadrogenism: Screening and diagnosis. J Clin Endocrinol Metab 1989;69:577–584.
16.
Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR: Idiopathic hirsutism: An uncommon cause of hirsutism in Alabama. Fertil Steril 1998;70:274–278.
17.
Hatch R, Rosenfield R, Kim MH, Treway D: Hirsutism: Implications, etiology and management. Am J Obstet Gynecol 1981;140:815–830.
18.
Seago SV, Ebling FJG: The hair cycle on the human thigh and upper arm. Br J Dermatol 1985;113:9–16.
19.
Pilsbury D, Shelley WB, Klingman AM: A Manual of Cutaneous Medicine. Philadelphia, Saunders, 1961, pp 273–283.
20.
Ludwig E: Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977;97:247–254.
21.
Paradisi R, Venturoli S, Pasquali R, Capelli M, Porcu E, Fabbri R, Flamigni C: Effects of obesity on gonadotropin secretion in patients with polycystic ovarian disease. J Endocrinol Invest 1986;9:139–144.
22.
Cusan L, Dupon A, Belanger A, Tremblay RR, Manhes G, Labrie F: Treatment of hirsutism with the pure antiandrogens flutamide. J Am Acad Dermatol 1990;23:462–469.
23.
Muderris II, Bayram F: Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism. J Endocrinol Invest 1999;22:165–168.
24.
De Leo V, La Marca A, Lanzetta D, Cariello PL, D’Antona D, Morgante G: Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin-releasing factor. Clin Endocrinol 1998;49:85–89.
25.
Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR: Treatment of hirsutism: Comparisons between different antiandrogens with central and peripheral effects. Fertil Steril 1999;73:445–451.
26.
Andrade RJ, Lucena MI, Fernàndez MC, Suàrez F, Montero JL, Fraga E, Hidalgo F: Fulminant liver failure associated with flutamide therapy for hirsutism (letter). Lancet 1999;353:983.
27.
Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ: The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2699–2705.
28.
Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M: The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: Evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952–960.
29.
De Leo V, Lanzetta D, D’Antona D, La Marca A, Morgante G: Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99–102.
30.
Muderris II, Bayram F, Guven M: Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 2000;14:38–41.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.